Wayne Weisman is Director at Recro Pharma, Inc. (REPH). They have made 11 open-market trades across 2 companies since 2015, most recently 2017-06-27.
CIK 0001588972
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 11 sales. Too few scored purchases to measure a record yet.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 100% | 86% | 100% |
| Avg Move | -12.2% | -14.9% | -31.7% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RWLK | SELL | 2017-06-26 | 2017-06-28 | $3.05 | $265K | -25.6% | -28.2% | -24.3% |
| RWLK | SELL | 2016-08-16 | 2016-08-17 | $6.29 | $315K | -6.3% | -6.5% | -55.1% |
| RWLK | SELL | 2016-08-15 | 2016-08-17 | $6.45 | $282K | -6.3% | -6.5% | -55.1% |
| RWLK | SELL | 2016-06-02 | 2016-06-06 | $7.89 | $109K | -15.1% | -16.1% | -22.2% |
| RWLK | SELL | 2016-05-25 | 2016-05-27 | $8.69 | $235K | -15.0% | -25.4% | -28.6% |
| RWLK | SELL | 2016-05-20 | 2016-05-23 | $9.08 | $101K | -11.3% | -25.1% | -30.3% |
| REPH | SELL | 2016-05-20 | 2016-05-23 | $6.45 | $97K | +33.3% | +24.5% | +35.2% |
| RWLK | SELL | 2016-01-15 | 2016-01-20 | $10.30 | $515K | -5.5% | +3.7% | -6.5% |
| REPH | SELL | 2015-11-27 | 2016-05-23 | $9.00 | $61K | +33.3% | +24.5% | +35.2% |
| REPH | SELL | 2015-11-23 | 2016-05-23 | $7.91 | $461K | +33.3% | +24.5% | +35.2% |
| REPH | SELL | 2015-11-23 | 2016-05-23 | $9.00 | $100K | +33.3% | +24.5% | +35.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.